0QNV Stock Overview
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Addex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.062 |
| 52 Week High | CHF 0.19 |
| 52 Week Low | CHF 0.062 |
| Beta | 1.91 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -24.97% |
| 3 Year Change | -93.16% |
| 5 Year Change | n/a |
| Change since IPO | -96.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QNV | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | -2.0% | 0.2% |
| 1Y | -25.0% | 6.0% | 6.3% |
Return vs Industry: 0QNV underperformed the UK Pharmaceuticals industry which returned 10.3% over the past year.
Return vs Market: 0QNV underperformed the UK Market which returned 8.4% over the past year.
Price Volatility
| 0QNV volatility | |
|---|---|
| 0QNV Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.0% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QNV's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0QNV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 23 | Tim Dyer | www.addextherapeutics.com |
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd Fundamentals Summary
| 0QNV fundamental statistics | |
|---|---|
| Market cap | CHF 5.51m |
| Earnings (TTM) | -CHF 12.67m |
| Revenue (TTM) | CHF 592.36k |
9.2x
P/S Ratio-0.4x
P/E RatioIs 0QNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QNV income statement (TTM) | |
|---|---|
| Revenue | CHF 592.36k |
| Cost of Revenue | CHF 6.69m |
| Gross Profit | -CHF 6.09m |
| Other Expenses | CHF 6.58m |
| Earnings | -CHF 12.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 24, 2025
| Earnings per share (EPS) | -0.13 |
| Gross Margin | -1,028.84% |
| Net Profit Margin | -2,139.51% |
| Debt/Equity Ratio | 0% |
How did 0QNV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/17 00:16 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Addex Therapeutics Ltd is covered by 13 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Meyer | Baader Helvea Equity Research |
| Leonildo Delgado | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |